GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (FRA:3OS) » Definitions » Institutional Ownership

Tempest Therapeutics (FRA:3OS) Institutional Ownership : 0.79% (As of Jan. 18, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Tempest Therapeutics's institutional ownership is 0.79%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Tempest Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Tempest Therapeutics's Float Percentage Of Total Shares Outstanding is 91.82%.


Tempest Therapeutics Institutional Ownership Historical Data

The historical data trend for Tempest Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tempest Therapeutics Institutional Ownership Chart

Tempest Therapeutics Historical Data

The historical data trend for Tempest Therapeutics can be seen below:

2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31
Institutional Ownership 1.17 1.29 1.29 1.24 1.24 1.09 1.33 1.32 0.79 0.79

Tempest Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Tempest Therapeutics Business Description

Traded in Other Exchanges
Address
2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Tempest Therapeutics Headlines

No Headlines